Potential opportunity in the development of new therapeutic agents based on endogenous and exogenous inhibitors of the proprotein convertases
Y Bontemps, N Scamuffa, F Calvo… - Medicinal Research …, 2007 - Wiley Online Library
Y Bontemps, N Scamuffa, F Calvo, AM Khatib
Medicinal Research Reviews, 2007•Wiley Online LibraryThe proprotein convertases (PCs) are responsible for the endoproteolytic processing of
various protein precursors (eg, growth factors, receptors, adhesion molecules, and matrix
metalloproteinases) implicated in several diseases such as obesity, diabetes,
atherosclerosis, cancer, and Alzheimer disease. The potential clinical and pharmacological
role of the PCs has fostered the development of various PC‐inhibitors. In this review we
summarized the recent findings on PCs inhibitors, their mode of actions and potential use in …
various protein precursors (eg, growth factors, receptors, adhesion molecules, and matrix
metalloproteinases) implicated in several diseases such as obesity, diabetes,
atherosclerosis, cancer, and Alzheimer disease. The potential clinical and pharmacological
role of the PCs has fostered the development of various PC‐inhibitors. In this review we
summarized the recent findings on PCs inhibitors, their mode of actions and potential use in …
Abstract
The proprotein convertases (PCs) are responsible for the endoproteolytic processing of various protein precursors (e.g., growth factors, receptors, adhesion molecules, and matrix metalloproteinases) implicated in several diseases such as obesity, diabetes, atherosclerosis, cancer, and Alzheimer disease. The potential clinical and pharmacological role of the PCs has fostered the development of various PC‐inhibitors. In this review we summarized the recent findings on PCs inhibitors, their mode of actions and potential use in the therapy of various diseases. © 2006 Wiley Periodicals, Inc. Med Res Rev, 27, No. 5, 631–648, 2007
Wiley Online Library